![](https://endpts.com/wp-content/uploads/2024/05/Jeb-Keiper-Nimbus-JPM24-feature.jpg)
Nimbus Therapeutics CEO Jeb Keiper at #JPM24 (Brian Benton Photography)
After $4B Takeda deal, Nimbus lays out ‘grand’ hopes for its next-gen immunotherapy drug
Just over a year ago, Nimbus Therapeutics closed one of the biggest single-drug deals in biotech, selling its TYK2 inhibitor to Takeda …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.